Newsfile Corp
24 Jul 2026, 13:53 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Regeneron's Phase III Fianlimab-Libtayo study failed to reach statistical significance for its primary endpoint of progression-free survival. — The failure of a Phase III trial for a key drug candidate represents a significant loss of potential future revenue and a failure of R&D investment.
-0.80Regeneron is facing a federal securities class action lawsuit alleging that executives made false or misleading statements regarding the Fianlimab-Libtayo study. — Securities litigation introduces legal risk and potential financial settlements, while damaging management credibility.
-0.40The lawsuit alleges that Regeneron concealed flawed statistical assumptions and a lack of clinical differentiation over standard therapies during the trial. — Allegations of systemic scientific flaws or data manipulation are more damaging to long-term trust than a simple trial failure.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a federal securities class action lawsuit following clinical trial failures and allegations of misleading investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
